Wojciech Jurczak MD
Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.
Most of his research activity in the first 15 years was related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in monotherapy or as an element of Z-BEAM conditioned ASCT.
During the last decade in Hematology, numerous drugs, with an alternative mechanism of action to classical cytostatics were developed.
Jagiellonian University Lymphoma he leads, participated in over 70 clinical trials, including phase I and phase I followed by expansion cohorts. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars. At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs.
He is a member of numerous scientific societies (ASH, ASCO, PLRG, EMCLN and ICOS) and consultant for EMA (European Medicines Agency). His research papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc. Cumulative IF > 650, H-index – 20 and citations > 3000.